
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
One of the most feared outcomes in children and adolescents with ADHD is the development of alcohol or drug abuse or dependence, referred to here as substance use disorders (SUD).






